Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
West Pharmaceutical Services ( (WST) ) has provided an announcement.
West Pharmaceutical Services reported fourth‑quarter 2025 net sales of $805.0 million, up 7.5% year on year, with organic growth of 3.3% and adjusted diluted EPS rising 12.1% to $2.04. Full‑year 2025 net sales grew 6.3% to $3.074 billion, driven by strong High‑Value Product Components demand, while free cash flow surged 69.6% to $468.9 million and the company repurchased $134.0 million of its own shares.
Performance in the Proprietary Products segment was led by a 20.3% jump in High‑Value Product Components sales, which accounted for nearly half of quarterly revenue, partially offset by a decline in High‑Value Delivery Devices tied to a prior‑year non‑recurring fee. Contract‑Manufactured Products grew modestly on demand for self‑injection devices for obesity and diabetes, and West issued 2026 guidance calling for mid‑single‑digit organic sales growth and high‑single‑ to low‑double‑digit adjusted EPS growth, underscoring confidence in continued momentum and operational execution.
The most recent analyst rating on (WST) stock is a Buy with a $295.00 price target. To see the full list of analyst forecasts on West Pharmaceutical Services stock, see the WST Stock Forecast page.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Neutral.
West Pharmaceutical Services shows solid financial performance and a positive earnings outlook, which are the most significant factors driving the score. However, the high valuation and mixed technical indicators slightly temper the overall assessment.
To see Spark’s full report on WST stock, click here.
More about West Pharmaceutical Services
West Pharmaceutical Services, Inc., headquartered in Exton, Pa., is a leading provider of innovative, high‑quality injectable solutions and services for drug developers. The company focuses on safe, effective containment and delivery of life‑saving and life‑enhancing medicines, operates more than 50 sites including 25 manufacturing facilities, and generated $3.07 billion in net sales in fiscal 2025.
Average Trading Volume: 843,625
Technical Sentiment Signal: Sell
Current Market Cap: $17.52B
For detailed information about WST stock, go to TipRanks’ Stock Analysis page.